Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced the granting of 1,850 restricted stock units (RSUs) to two newly-hired employees as of March 31, 2025.
The RSU awards, granted under the Company's 2022 Inducement Stock Incentive Plan, will vest over three years, with 33 1/3% vesting on each anniversary of the Grant Date. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements. Additionally, the RSUs include an acceleration clause allowing immediate full vesting if employment is terminated for 'good reason' or without 'cause' within one year of a change in control event.
Karyopharm Therapeutics (Nasdaq: KPTI), un'azienda farmaceutica in fase commerciale focalizzata su nuove terapie per il cancro, ha annunciato l'assegnazione di 1.850 unità azionarie limitate (RSU) a due nuovi dipendenti a partire dal 31 marzo 2025.
Le assegnazioni di RSU, concesse ai sensi del Piano di Incentivazione Azionaria per Induzione 2022 della Società, matureranno in tre anni, con il 33 1/3% che matura ogni anniversario della Data di Assegnazione. Le assegnazioni sono state effettuate in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) come incentivi all'impiego. Inoltre, le RSU includono una clausola di accelerazione che consente la maturazione immediata totale se l'impiego viene interrotto per 'buon motivo' o senza 'giusta causa' entro un anno da un evento di cambio di controllo.
Karyopharm Therapeutics (Nasdaq: KPTI), una empresa farmacéutica en etapa comercial centrada en nuevas terapias contra el cáncer, ha anunciado la concesión de 1,850 unidades de acciones restringidas (RSU) a dos empleados recién contratados a partir del 31 de marzo de 2025.
Las asignaciones de RSU, otorgadas bajo el Plan de Incentivos de Acciones por Inducción 2022 de la Compañía, se consolidarán en tres años, con el 33 1/3% consolidándose en cada aniversario de la Fecha de Concesión. Las concesiones se realizaron de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4) como incentivos de empleo. Además, las RSU incluyen una cláusula de aceleración que permite la consolidación total inmediata si el empleo se termina por 'buena razón' o sin 'causa' dentro de un año de un evento de cambio de control.
Karyopharm Therapeutics (Nasdaq: KPTI), 새로운 암 치료에 집중하는 상업 단계의 제약 회사가 2025년 3월 31일 기준으로 두 명의 신입 직원에게 1,850개의 제한 주식 단위 (RSU)를 부여했다고 발표했습니다.
RSU 보상은 회사의 2022 유도 주식 인센티브 계획에 따라 부여되며, 3년 동안 분할 지급됩니다, 부여일의 매년 기념일에 33 1/3%가 지급됩니다. 이 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유인으로 이루어졌습니다. 또한, RSU에는 '정당한 사유'로 고용이 종료되거나 '사유 없이' 통제 변경 이벤트 발생 후 1년 이내에 즉각적으로 전체 지급이 가능하도록 하는 가속 조항이 포함되어 있습니다.
Karyopharm Therapeutics (Nasdaq: KPTI), une entreprise pharmaceutique en phase commerciale axée sur de nouvelles thérapies contre le cancer, a annoncé l'octroi de 1 850 unités d'actions restreintes (RSU) à deux nouveaux employés à compter du 31 mars 2025.
Les attributions de RSU, accordées dans le cadre du Plan d'Incentive d'Actions par Induction 2022 de la Société, seront acquises sur trois ans, avec 33 1/3 % acquérant chaque anniversaire de la Date d'Attribution. Les attributions ont été effectuées conformément à la Règle de Cotation Nasdaq 5635(c)(4) en tant qu'incitations à l'emploi. De plus, les RSU incluent une clause d'accélération permettant une acquisition totale immédiate si l'emploi est résilié pour 'bonne raison' ou sans 'cause' dans l'année suivant un événement de changement de contrôle.
Karyopharm Therapeutics (Nasdaq: KPTI), ein pharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf neuartige Krebstherapien konzentriert, hat die Gewährung von 1.850 eingeschränkten Aktieneinheiten (RSUs) an zwei neu eingestellte Mitarbeiter ab dem 31. März 2025 bekannt gegeben.
Die RSU-Zuweisungen, die im Rahmen des Aktienincentiveplans zur Induktion 2022 des Unternehmens gewährt wurden, werden über drei Jahre fällig, wobei 33 1/3% an jedem Jubiläum des Gewährungsdatums fällig werden. Die Zuweisungen wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Beschäftigungsanreize vorgenommen. Darüber hinaus enthalten die RSUs eine Beschleunigungsklausel, die eine sofortige vollständige Fälligkeit ermöglicht, wenn das Beschäftigungsverhältnis aus 'gutem Grund' oder ohne 'Ursache' innerhalb eines Jahres nach einem Kontrollwechselereignis beendet wird.
- None.
- None.
Each RSU award will vest over three years, with 33 1/
In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the 2022 Inducement Stock Incentive Plan, as amended).
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302412200.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
How many RSUs did Karyopharm Therapeutics (KPTI) grant in March 2025?
What is the vesting schedule for KPTI's March 2025 RSU grants?
What happens to KPTI's RSU grants in case of a change in control event?
Under which plan were the KPTI RSUs granted in March 2025?
